Fuxiang Pharmaceutical (300497.SZ) released its first three quarters performance, with net profit attributable to the parent company of 403 million yuan, turning losses into profits year-on-year.

Zhitong Finance APP News, Fuxiang Co., Ltd. (300497.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 1.55 billion yuan, a year-on-year increase of 101.49%; net profit attributable to shareholders of the listed company was 403 million yuan, turning from loss to profit year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 373 million yuan; basic earnings per share were 0.75 yuan. The company's performance growth was mainly due to the increase in both volume and price of its lithium battery electrolyte additive business during the reporting period, which increased profits.